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ABSTRACT 
Opioid and heroin use has increased dramatically over the past two decades. This issue 
has public health significance as overdose rates and usage rates of these drugs have never been 
higher. This increase in use has been driven primarily by availability. The population considered 
most at risk for opioid/heroin abuse is young, white males. There is a significant comorbidity in 
opioids and alcohol and alcohol abuse has increased among this young white male population as 
well. There is evidence that the presence of medical marijuana in states is associated with lower 
rates of overdose from opioids and heroin. There is also evidence that marijuana acts as a 
substitute for alcohol in places where it is legal. The objective of this study is to look at the 
association between overdose rates by state, related to opioids, heroin or alcohol and the 
presence of medical marijuana in those states. We want to evaluate how state policies, like the 
presence of prescription drug monitoring programs, as well as socio-economic factors affect the 
rate of these deaths. Fixed-effect linear models were fit in order to do primary and secondary 
analyses of medical marijuana’s effects on overdose deaths.  
Medical marijuana was found to have a positive effect on the rates of overdoses related to 
opioids, heroin or alcohol. A secondary analysis showed a negative cumulative year effect. This 
suggests that overdose rates are initially higher in places that have legalized medical marijuana 
but that as time passes overdose rates fall. The actual magnitude of the effects of medical 
marijuana is small when compared to our socio-economic covariates. These results suggest that 
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marijuana policy, while potentially useful in combating this drug epidemic, is less important than 
socio-economic factors in curbing overdose deaths.  
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1.0  INTRODUCTION 
1.1 PROBLEM 
Since the mid-1990s prescription opioid and heroin abuse have increased in a dramatic 
fashion. This opioid crisis, along with a corresponding increase in alcohol abuse has contributed 
to a rising death rate amongst middle-aged white Americans.  Trends in this increase in the death 
rate have emerged. According to the CDC, “Drug overdose death rates in the United States have 
more than tripled since 1990 and have never been higher. In 2008, more than 36,000 people died 
from drug overdoses, and most of these deaths were caused by prescription drugs” 6 
Furthermore, according to the NIH’s National Institute on Drug Abuse, or NIDA, “…an 
estimated 52 million people (20 percent of those aged 12 and older) have used prescription drugs 
for nonmedical reasons at least once in their lifetimes,” and, “…about 1 in 12 high school seniors 
reported past-year nonmedical use of the prescription pain reliever Vicodin in 2010, and 1 in 20 
reported abusing OxyContin”. 25 According to NIDA’s National Survey Results on Drug use, in 
2003 opioid analgesics were the second most abused drug amongst high school seniors, behind 
marijuana. 14 In the period from 1998 to 2002, mentions of opioid analgesics in medical 
examiner cases increased in 28 of 31 reporting areas of the United States. 13  
It is clear that opioid abuse is a major public health issue affecting the United States. In 
addition to the increases in drug abuse and overdose deaths, this issue has had a significant 
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economic impact. Based on estimates from the 2007 National Survey on Drug Use and Health 
(NSDUH), total societal costs to the US were said to be about $55.7 billion in that year. (12) In 
order to fully address the problem of opioid abuse and increasing heroin abuse it is important to 
understand how this form of drug abuse manifests itself in the US.  
1.2 REASONS 
One of the biggest driving factors in opioid abuse is the availability of opioid analgesics. 
According to the CDC, “Sales of prescription opioids in the U.S. nearly quadrupled from 1999 to 
2014,” and deaths related to those drugs have increased similarly. 10 From 1990 to 1996 the 
biggest increases in prescribed opioids were for oxycodone, 402% increase, fentanyl, 226%, 
hydromorphone, 96% and morphine, 783%. 16 The connection between the increasing amounts 
of prescription drugs in the American populous and the increasing number of deaths related to 
those drugs is apparent. Opioid analgesics are prescribed in two ways: for short-term and long-
term pain management. Addiction and abuse are generally rare for patients on a short-term 
opioid prescription. Long-term patients on the other hand, are at a significantly increased risk for 
addiction. 15 Though short-term pain management patients do not experience an increased risk of 
drug abuse and addiction, the presence of pain medication in a household does pose a source of 
risk for other members of the home. 26  
Availability of opioids is only one explanation for increases in opioid abuse. In a study of 
VA patients from 2000 to 2005, researchers looked at risk factors for opioid abuse among 
veterans. They found that a diagnosis of non-opioid substance abuse was the strongest predictor 
of opioid abuse and addiction. They also found that mental health disorders were strong 
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predictors; the fact that there are so many more patients with mental health disorders, in this 
study at least, suggests that mental health disorders account for more of the attributable risk for 
opioid abuse and addiction than non-opioid substance abuse. 27 
In order to deal with the increases in opioids abuse it is important to understand which 
portion of the population is most at risk for opioid abuse and addiction. It has been shown that 
certain factors are positively associated with opioid abuse: patients with multiple opioid 
prescriptions from multiple pharmacies and doctors, patients who refill their prescription opioids 
early, and other measures of actual drug use are the best predictors of opioid abuse. Apart from 
actual usage, certain demographic factors are also very much associated with opioid abuse: 
young white men, 18-34, are at higher risk for opioid abuse than others. 17 There is comorbidity 
in opioids and alcohol. In fact, there is comorbidity in alcohol with most illicit drugs. In the 
context of opioid abuse, alcohol is an important drug to also consider, as alcohol use in 
conjunction with opioid use is very dangerous and accidental overdoses when the two substances 
are combined are not uncommon. A study of drug overdoses in New Mexico found that over the 
time period 1990-2005 there was a 196% increase in single-drug category overdose deaths that 
was driven primarily by heroin alone and opioids alone. The same study also found that there 
was a 148% increase in multiple-drug category overdose deaths and that this was fueled mainly 
by heroin/alcohol and heroin/cocaine. 20 It is interesting to note that young men in the US are 
also at increased risk for alcohol abuse and dependence, similar to how they are at increased risk 
for opioid abuse. A study using results from the National Epidemiologic Survey on Alcohol and 
Related Conditions found that alcohol abuse and dependence are both more prevalent among 
young men, particularly whites and those with a low income. 18  
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Based on all of this information we can identify the most pressing drug abuse issue in the 
US. Prescription opioid abuse has been a growing issue for much of the last two decades and 
heroin abuse has seen a similar trend, as opioid abusers eventually turn to the cheaper and more 
potent alternative. Opioids and heroin have a significant comorbidity with alcohol and the 
combination of the two substances has had an increasing contribution to overdose deaths. The 
demographic considered most at risk for abuse and dependence on opioids and alcohol are young 
men, typically in the 18-34 age range and typically with some kind of risk factor for drug abuse 
such as being on a long term pain management program, having mental health issues, or having 
abused drugs in the past. In addition, particularly for alcohol, poor whites are considered more at 
risk for drug abuse and dependence.  
1.3 POSSIBLE SOLUTIONS 
There is evidence that the legalization of medical marijuana is correlated with a reduction 
in the increasing rate of heroin overdoses. 3 Other studies have shown links between marijuana 
use and a decreased need for opioids, at least in long term palliative care 4 as well as a decreased 
rate of alcohol related traffic fatalities.7 Legalized medical marijuana can be thought of as a stand 
in for more liberal attitudes towards marijuana and drug use in general.2 Based on these findings, 
it may be appropriate to think of marijuana use as having some kind of protective effect when it 
comes to opioid/heroin and alcohol abuse.  
Conversely, the opposite could be true. States that have legalized medical marijuana tend 
to have more lax attitudes towards drug use as well as a greater prevalence of marijuana use 
among the high school aged population. Studies have shown that the younger an individual is at 
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the onset of marijuana or alcohol use, the more likely they are to abuse drugs in the future. 2,21,5 
In this case it could be argued that medical marijuana laws are evidence of a more at risk 
population for drug abuse and that the presence of such laws are indicative of a populous that is 
more likely to abuse and therefore suffer the ill effects of opioids, heroin and alcohol.  
 
Figure 1. States with medical marijuana laws during the study period 
1.4 OBJECTIVE 
The primary objective of this study is to look at the relationship between overdose deaths 
related to alcohol and drug abuse, specifically prescription opioids and heroin, and the presence 
of statewide medical marijuana laws. If the presence of legal medical marijuana is associated 
with a reduction in these types of deaths than it could be evidence that marijuana could be 
considered a substitute for opioids and heroin both medically, in the treatment of pain, chronic 
and otherwise, and recreationally, where the negative health effects of marijuana are far less 
severe than those of opioids and heroin. A reduction in the volume of prescription drugs would 
 6 
lead to a decrease in abuse of prescription drugs and lead to fewer individuals progressing from 
opioids to heroin. Secondary objectives include measuring the impact of factors such as poverty 
and education on overdoses from drug and alcohol abuse. The hope in building this model is to 
measure not only the impact of both state-wide policies, MMLs and PDMPs, but also to measure 
the impact of socio-economic factors.  
1.5 DATA SOURCES 
Data were obtained on all 50 states plus the District of Columbia (N=51) from the time 
period 2003-2014 (T=12) on a number of state policies, socio-economic factors and non-
intentional overdose deaths with either an opioid, heroin, or alcohol contributing cause of death. 
The state policies that are of primary concern are implementation of medical marijuana laws 
(MMLs) and/or prescription drug monitoring programs (PDMPs).9 PDMPs are designed to track 
the prescribing and dispensing of prescription drugs to patients and can give prescribers 
information on a patient’s prescription drug history as well as monitor suspected abuse and 
diversion, such as selling drugs.11  This information better allows states to find out which 
individuals are engaged in the drug using behaviors described earlier: having multiple opioid 
prescriptions from multiple pharmacies or doctors.17 
Besides this policy information, data on socio-economic factors including education 
level, individuals in poverty and insurance status were obtained from the Census Bureau over the 
study period. Individuals at risk for drug abuse tend to have a lower income than those 
considered less at risk. Poverty and education level are very closely related and insurance status 
gives us an idea of the portion of each state’s population receiving adequate healthcare. 
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Overdose data by year and state was obtained from the CDC’s WONDER database. Of interest 
are non-intentional overdose deaths with a contributing cause of death pertaining to either 
opioids, heroin and other narcotics, or alcohol.  
The overdose mortality rate for deaths related to opioid analgesics, heroin and alcohol in 
the years 1999 to 2014 for every state was abstracted from the Center for Disease Control’s 
Wide-ranging Online Data for Epidemiologic Research interface for multiple-cause of death. 
Opioid analgesic and heroin overdose deaths were defined as overdoses of any intent 
(International Statistical Classification of Diseases,10th revision [ICD-10], codes X40-X45 and 
Y10-Y15) where either an opioid analgesic, heroin or narcotic, or alcohol were coded for 
(extension codes T40.0-T40.4, T36-T39, T50.9, T151.0-T151.9). This captures overdose deaths 
where an opioid was involved including cases related to polypharmacy, illicit narcotics and 
alcohol.  
State-level time varying economic factors were also obtained from the U.S. Census 
Bureau. These include individuals in poverty, insurance status and education levels by state with 
racial breakdowns. In addition to these three demographic and socio-economic measures, data 
was also obtained on which states have prescription drug monitoring programs (PDMPs) 9 as 
well as which states have medical marijuana laws (MMLs) and in what years these programs and 
laws were implemented.  
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2.0  METHODS 
2.1 NORMAL FIXED-EFFECTS MODELS 
The data used in this study was time-series cross-sectional (TSCS) and consisted of 
comparable time-series data observed over a number of units. In this case our time-series was 
each year 2003 to 2014 and our units were all 50 states plus Washington D.C.; N=51 and T=12. 
TSCS data resembles panel data and both are forms of multilevel or hierarchical data whereby 
lower-level observations are grouped by some characteristic of interest, in this case states.22 
There are several advantages to analyzing TSCS data, according to Worrall and Pratt’s paper, 
“Estimation Issues Associated with Time-Series—Cross-Section Analysis in Criminology.” 
TSCS estimation typically reduces estimation bias, allows for the specification of multiple 
models and reduces the problems from data multicollinearity.24  
The TSCS models were based on the generic form: 
yi,t = xi,tβ + εi,t ;  i = 1, . . . , N; t = 1, . . . , T  (1) 
yi,t ~ N(μ, σ2) 
yi,t  is the log of the age-adjusted death rate related to overdose/100,000 population for 
state i at time t. xi,t is a vector of covariate data for state i  at time t and β is the coefficient on that 
covariate. εi,t is the error term.  
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This assumed a rectangular data structure, each of N units was observed for all T times. 
This model assumed no error structure for εi,t, error terms were considered independent for all i 
and t. This simple model represented a good method of estimating TSCS data. Units were fixed, 
not sampled, and N was neither too small nor too large, falling near the middle of the general 
rule that N=10 to 100. T was also large enough (>10) so that time-averages made sense.  
Equation (1) provided a good model based on the assumption that all units were fit by the 
same model with the only variation between units being the independent variables, xi,t. Equation 
(1) failed to account for heterogeneity between units however. The simplest way to account for 
heterogeneity between units was to allow for the inclusion of an intercept value for each unit, αi, 
which represents the fixed effects of state i on the dependent variable. A fixed effects model can 
be expressed simply as: 
yi,t = xi,tβ + αi + εi,t ;  i = 1, . . . , N; t = 1, . . . , T  (2) 
αi ∼ N(0, σ2µ) 
That is, the fixed effects intercept only shifted the regression line for each specific unit up 
or down, regression lines for each state remained parallel. This allows us to estimate the effect of 
state-level time-varying factors across all states while still accounting for differences across 
states.  
We use fixed-effect models when we are mainly interested in variables that change over 
time, in this case measures of poverty, insurance coverage, and education, as well as the presence 
of prescription drug monitoring programs (PDMPs) and medical marijuana laws (MMLs). In a 
fixed-effect model each unit, or state, has its own characteristics that may or may not have an 
effect on the independent variables. This kind of state-level heterogeneity is generally described 
as some prevalent attitude or condition present in the state that is difficult to measure. For 
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example, two states could lean conservative politically, but this is not necessarily a good 
representation of both states’ underlying attitudes towards drug policy. Alaska and Texas are 
similar electorally but have totally opposite medical marijuana laws over the study period. It 
would be inaccurate to model both states exactly the same and introducing a fixed-effect model 
allows for differences between individual unit models.   
This concept of introducing fixed effects to a model extends beyond just the units, or 
states, measured and can be applied to the time factors in the study. The study period here is 
2003 to 2014, and while overdose rates have risen throughout that time period, they have not 
necessarily risen uniformly from year-to-year or state-to-state or even region-to-region. Time 
fixed-effects are treated the same as unit fixed-effects, another intercept value is included in 
order to represent the fixed effects of each year within the study period and their effect on the 
dependent variable. A model with both unit and time fixed-effects can be expressed as: 
yi,t = xi,tβ + αi + φt + εi,t ; i = 1, . . . , N; t = 1, . . . , T  (3) 
φt ~ N(0, σ2µ) 
Where φt behaves in the same way that αi does, except φt applies to time-effects.  
In this type of model we assume a correlation between the error term and a unit’s 
independent variables in order to account for the unseen fixed-effects of a specific unit. The 
fixed-effects remove the effect of those time-invariant characteristics to better estimate the effect 
of our independent variables on our outcome variables. The simplest way to test for 
heterogeneity and the need to include fixed-effects is to use a Hausman test to compare the F 
statistics from equation (3), the model with the fixed-effect intercepts, to equation (1), the model 
without the fixed-effect intercept. When deciding between including both unit and time fixed-
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effects we can look at the F statistics comparing equation (2) to (1) and comparing (3) to (1) and 
decide which model better represents the data.  
2.2 POISSON FIXED-EFFECTS MODELS 
The concept of fixed-effects regression is not limited solely to linear models. Fixed-
effects can be applied to other regression models and in this case we have considered the 
possibility that a Poisson model is potentially more appropriate for the data used in this study. 
The generic form of this model can be expressed as: 
E[yit | xit ] = μit = exp(x’it β)   (4) 
Where μit is the dependent variable of interest, in this case the log of the age-adjusted 
death rate/100,000 population and xi,t is a vector of explanatory variables for unit i at time t. As 
in the linear fixed-effects models we can model the unobserved heterogeneity between units and 
years, expressed in αi and φt as individual and time specific effects. That effect is multiplicative 
in the conditional mean rather than additive, as expressed here:  
E[yit | xit; αi , φt ] = μit = αi φt exp(x’it β)   (5) 
Note: an intercept term is not expressed as it is folded into the fixed-effects terms.29  
 
In a random-effects model we would treat the panel data as a single cross-section and 
estimate our parameters of interest after making some assumption about the distributions of 
αi.and φt. The fixed-effects model makes minimal assumptions about αi or φt. This approach can 
be justified by the fact that if there were only a few individuals observed over many time periods, 
then all αi’s and φt’s could be treated as parameters to be estimated.30  
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In summary, fixed-effects models have broader extensions than just linear regression and 
panel data, or time-series cross-sectional data, can be modeled using many techniques while still 
accounting for and measuring unobserved heterogeneity between units and time periods.  
2.3 PRIMARY/SECONDARY MML ANALYSIS AND FINAL MODELS 
Model diagnostics were used to assess the appropriateness of a Normal model versus a 
Poisson model. Distributions of dependent variables, AIC/BIC measures, as well as residual 
plots were compared in order to choose the best method of estimation. We also looked at 
multicollinearity between our socio-demographic variables. Based on these various measures we 
concluded that a linear TSCS fixed-effects regression model based on a Normal distribution was 
most appropriate for these data.  
Using linear time-series cross-sectional regression models, we analyzed the association 
between medical marijuana laws and opioid and alcohol related deaths. For our dependent 
variable we used the log of the age-adjusted death rate per 100,000 population related to opioid 
and/or alcohol use. The primary independent variable of interest is the presence of medical 
marijuana laws, which are modeled in two ways. In the first regression model a state and year-
specific indicator variable was included for the presence of medical cannabis laws. All years 
prior to passage are coded as 0 and all years after passage are coded as 1. Because laws could be 
passed at different times during a specific year, the year of passage is coded as a fraction. For 
example, a cannabis law passed on July 1st would be coded as 0.5 in that year.  
In the second model we allowed the effect of medical marijuana laws to vary based on 
time elapsed since the passage of the law. In order to account for delays in patient registration, 
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distribution of identification cards and establishment of dispensaries, where applicable, we 
included a variable of years since implementation of MMLs. This allowed us to measure the 
cumulative effect of multiple years of legal medical marijuana.  
These models were fit two different ways. First, demographic data was used for each 
state’s total population; annual poverty rates, education level and insurance status were taken 
from all residents of each state. Second, this same demographic data was used but for the white 
population only. As stated earlier there is evidence to suggest that this problem 
disproportionately effects the white population and fitting each model with demographic data 
from the total population and just the white population allowed us to look at these differences.  
Finally, this same two model analysis, for both the total population and the white 
population was run again, this time on death rates corresponding only to opioid and heroin 
related deaths, without alcohol. This was done in order to look at the problem of drug abuse 
without the effects of polypharmacy and to see if there were significant differences in how our 
model predicted these drug abuse deaths.  
To review, a total of eight models were fit. We can divide these up by the cause of death, 
opioids, heroin and/or alcohol or opioids and heroin only. Primary and secondary MML analysis 
were carried out and models were fit with socio-demographic data from the total population and 
again for the white population only. These eight models are listed in table 1.  
Table 1. All eight models fit for both overdose categories, two levels of MML analysis and population 
subgroups 
Cause of Death Primary MML analysis Secondary MML analysis 
Opioids, heroin and/or alcohol Total Pop. Total Pop. 
White Pop. White Pop. 
Opioids and heroin only  Total Pop. Total Pop. 
White Pop. White Pop. 
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Models were fit using seven state level factors: 
1. Annual percentage of state population living in poverty 
2. Annual percentage of state population with no more than a high school diploma 
3. Annual percentage of state population with health insurance 
4. An interaction term of 1. And 2.  
5. Medical marijuana laws (MML) by state 
6. Presence of prescription drug monitoring programs (PDMP) by state 
7. State-specific years since implementation of MML 
Number 3, the annual percentage of state population with health insurance, was removed 
from the final models as it added little to the model and was not significant. Number 7, our years 
since implementation of MMLs variable is only included in the secondary MML analysis.3 
All analysis was done in SAS for a combination of cross-sectional and time-series data, 
otherwise known as panel data. Two-way fixed effects models fit with the intercept suppressed 
were fit. Primary MML analysis models can be represented by following equation: 
 
Yit = αN + φt + β1(% Population in Poverty) + β2(%  Population Finished no more than 
HS) + β3(% Poverty * % Finished HS) +  β4(MML)  + β5(PDMP)  + ɛit 
 
Secondary MML analysis models can be represented by the following equation: 
 
Yit = αN + φt + β1(% Population in Poverty) + β2(% Finished HS) + β3(% Poverty * % 
Finished HS) +  β4(MML)  + β5(PDMP)  + β6(years since MML implementation) + ɛit 
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3.0  RESULTS 
3.1 DISTRIBUTIONS AND DESCRIPTIVES 
Eight states had medical marijuana laws prior to the beginning of the study period in 
2003. Twelve more states, including Washington D.C., passed MMLs at some point during the 
study period, 2003-2014. Figure 2 shows the mean age-adjusted death rates for states with and 
without MMLs were plotted over the study period. 
 
 
 
Figure 2. Mean age-adjusted death rates by state MML policy 
 
In order to analyze the distribution of overdose deaths across the nation, the natural log of 
the age-adjusted death rate/100,000 population was plotted over the entire study period for both 
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causes of death, those relating to opioids, heroin or alcohol, or those relating to opioids or heroin 
only. The distributions of the dependent variables are pictured in figures 3 and 4.  
 
 
Figure 3. Distribution of overdose deaths related to opioids, heroin or alcohol, 2003-2014 
 
 
Figure 4. Distribution of overdose deaths related to opioids and heroin only, 2003-2014 
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The distribution of the log of the age-adjusted death rate appears normal but we want to 
evaluate whether or not we can treat this data as normally distributed. Figures 5 and 6 show Q-Q 
plots of our data. There appears to be a slight right-skewedness to the distributions of our 
outcome data. A Shapiro-Wilk test of normality rejects the assumption of normality (p=<.05) for 
both outcomes, but this test is sensitive to small sample sizes; here our N is only 51. For this 
reason we consider both Normal and Poisson models. 
 
 
Figure 5. Q-Q plot of log age-adjusted death rate/100,000 for overdoses related to opioids, heroin or 
alcohol 
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Figure 6. Q-Q plot of log age-adjusted death rate/100,000 for overdoses related to opioids and heroin only 
 
 
In order to look at some of our demographic data in states with and without MMLs the 
percentage of states’ population living in poverty as well as percentage of states’ population 
having finished no more than high school were plotted over the study period in Figures 7 and 8.  
The most striking feature from these figures is the difference in education in states with 
MMLs. Overdose rates related to opioids, heroin or alcohol as well as the percentage of a state’s 
population living in poverty are not drastically different when we compare states with and 
without MMLs. Education, however, had a much higher percentage of the population from states 
without MMLs having finished no more than high school. Regardless of these differences a few 
trends emerge: overdose deaths are rising everywhere, poverty is getting worse and education 
levels, as measured by percentage of residents completing more than just a high school diploma, 
are rising.  
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Figure 7.  Percentage of population living in poverty by state MML policy 
 
 
 
 
 
Figure 8. Percentage of population with no more than a high school diploma by state MML policy 
 
 
Important results are abstracted in tables 1-5. Tables 1-4 contain coefficients, standard 
deviations and p-values for covariates used in the 8 different fixed-effect linear models discussed 
earlier. Because of questions about the normality of our outcome variable, models were also fit 
using fixed-effects Poisson regression and compared on the basis of AIC and BIC, which is 
shown in table 5. It should be noted that while the magnitude and significance of predicted 
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coefficients were not uniform between the Normal and Poisson models, the direction, both 
positive and negative, of those coefficients were the same.  
3.2 OPIOIDS, HEROIN OR ALCOHOL RESULTS 
In the first model, illustrated in table 2, results show that the presence of MMLs is 
positively associated with overdose deaths related to opioids, heroin or alcohol when using 
covariates from the full population as well as the white population. The interaction term of 
education and poverty is also positively associated with these overdose deaths but at a much 
greater value. PDMPs are negatively associated with overdose deaths but aren’t statistically 
significant in this analysis.  
Table 2. Primary MML analysis for cause of death codes related to opioids, heroin, or alcohol 
Covariates All White  
% Population in Poverty 
-8.88963 
(3.0106) 
0.0033 
-11.0721 
(2.6003) 
<.0001 
 
Coeff. 
(Std Dev) 
p-value 
 
% Population w/ no more than HS diploma 
-5.73844 
(1.7658) 
0.0012 
-5.0013 
(1.291) 
0.0001 
 
Interaction term (Poverty and Education) 
36.8561 
(12.1223) 
0.0025 
46.62059 
(10.7353) 
<.0001 
 
MML 
0.151224 
(0.0389) 
0.0001 
0.145903 
(0.0383) 
0.0002 
 
PDMP 
-0.03361 
(0.0297) 
0.2582 
-0.0389 
(0.0293) 
0.1851 
 
Opioids, Heroin or Alcohol (Primary MML Analysis) 
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Table 3 shows a secondary analysis of MMLs based on the same models as in table 2, 
except for the inclusion of an additional covariate. A years-since-implementation of MMLs 
variable is added to the model to gain some perspective about the cumulative, multi-year effects 
of MMLs. In this secondary analysis the years since implementation variables has a negative 
effect on overdose deaths, suggesting that multiple consecutive years of MMLs has a beneficial 
effect with respect to overdoses related to opioids, heroin, and alcohol. The effects of covariates 
are similar in direction and magnitude, regardless of whether they are taken from the full 
population or the white population.  
 
Table 3. Secondary MML analysis for cause of death codes related to opioids, heroin, or alcohol 
Covariates All White  
% Population in Poverty 
-6.82718 
(2.96) 
0.0215 
-9.05053 
(2.5671) 
0.0005 
 
Coeff. 
(Std Dev) 
p-value 
 
% Population w/ no more than HS 
diploma 
-4.19462 
(1.7453) 
0.0166 
-3.79731 
(1.2808) 
0.0032 
 
Interaction term (Poverty and Education) 
28.62075 
(11.9169) 
0.0167 
38.05519 
(10.6047) 
0.0004 
 
MML 
0.200756 
(0.0391) 
<.0001 
0.195037 
(0.0386) 
<.0001 
 
PDMP 
-0.02736 
(0.029) 
0.3454 
-0.03101 
(0.0287) 
0.2796 
 
# Years of MML Implemented 
-0.02753 
(0.00513) 
<.0001 
-0.02674 
(0.0051) 
<.0001 
 
Opioids, Heroin or Alcohol (Secondary MML Analysis) 
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3.3 OPIOIDS/HEROIN ONLY RESULTS 
Tables 4 and 5 show results for similar models to tables 2 and 3, except the outcome 
variable here is changed to the log of overdose deaths related to opioids or heroin only. These 
models give much the same results as presented in tables 2 and 3, positive associations between 
MMLs and overdose deaths but negative associations when accounting for multiple years of 
legalization. The interaction term of education and poverty is still the most positively significant 
variable and the largest in magnitude. The main difference between these models and those 
presented in tables 2 and 3 is that PDMPs are now statistically significant, which makes a certain 
amount of sense as alcohol overdoses are now omitted from the outcome variable. Table 6 
contains AIC and BIC values for the Normal based models that are abstracted out in tables 2 
through 5 as well as for the Poisson based models that we considered. It is clear from those 
results that the Normal based fixed-effects models better fit the data. Residual diagnostics for all 
eight models fit are in figures 11-18 in the appendix.  
 
Table 4. Primary MML analysis for cause of death codes related to opioids and heroin only 
Covariates All White  
% Population in Poverty 
-9.32898 
(3.1399) 
0.0031 
-10.6291 
(2.816) 
0.0002 
 
Coeff. 
(Std Dev) 
p-value 
 
% Population w/ no more than HS 
diploma 
-6.37582 
(1.8403) 
0.0006 
-5.31207 
(1.3734) 
0.0001 
 
Interaction term (Poverty and 
Education) 
39.44566 
(12.6382) 
0.0019 
45.70408 
(11.5654) 
<.0001 
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Table 4 Continued  
MML 
0.149808 
(0.0406) 
0.0002 
0.148435 
(0.0402) 
0.0002 
 
PDMP 
-0.06201 
(0.0309) 
0.0002 
-0.06777 
(0.0306) 
0.0274 
 
Opioids or Heroin (Primary MML Analysis) 
 
 
 
Table 5. Secondary MML analysis for cause of death codes related to opioids and heroin only 
Covariates All White  
% Population in Poverty 
-7.1716 
(3.0841) 
0.0204 
-8.37766 
(2.7781) 
0.0027 
 
Coeff. 
(Std Dev) 
p-value 
 
% Population w/ no more 
than HS diploma 
-4.7488 
(1.8174) 
0.0092 
-3.99371 
(1.3618) 
0.0035 
 
Interaction term (Poverty 
and Education) 
30.79889 
(12.4129) 
0.0134 
36.18615 
(11.4176) 
0.0016 
 
MML 
0.202031 
(0.0407) 
<.0001 
0.199911 
(0.0404) 
<.0001 
 
PDMP 
-0.05544 
(0.03031) 
0.0663 
-0.05954 
(0.0299) 
0.047 
 
# Years of MML 
Implemented 
-0.02898 
(0.00533) 
<.0001 
-0.02837 
(0.00532) 
<.0001 
 
Opioids or Heroin (Secondary MML Analysis) 
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Table 6. AIC/BIC comparison of linear models vs. poisson models  
    Primary MML analysis Secondary MML analysis 
Cause of Death Model AIC BIC AIC2 BIC3 
Opioids, heroin, alcohol (all) Normal -321.865 -22.8739 -351.522 -48.1337 
Poisson 1753.022 2047.6163 1754.55 2053.5413 
Opioids, heroin, alcohol (white) Normal -330.963 -31.9715 -359.189 -55.8005 
Poisson 1752.957 2047.5515 1754.503 2053.4942 
Opioids and heroin only (all) Normal -272.119 26.4172 -302.56 0.3669 
Poisson 1720.449 2014.5951 1721.935 2020.4711 
Opioids and heroin only (white) Normal -276.758 21.7788 -305.985 -3.0587 
Poisson 1720.426 2014.5719 1721.924 2020.4601 
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4.0  ANALYSIS/DISCUSSION 
The most striking result is that our model shows a positive relationship between the 
presence of MMLs in a state and the log of the age-adjusted death rate related to opioids or 
alcohol. This is the opposite of what was found in Medical Cannabis Laws and Opioid Analgesic 
Overdose Mortality in the United States, 1999-2010.3 There are a number of explanations for 
this. First, ICD codes used to examine overdose deaths are not uniform. The codes used in this 
study include alcohol related deaths as well as a more comprehensive list of extension codes that 
we believe captures a more complete picture of the drug abuse issue. Second, even though the 
independent variables used in the two studies are similar they are not the same. Here we are 
interested in education, poverty and how the two interact with each other, rather than just the 
state unemployment rate.  Also, while both studies include MML and PDMP policies, we do not 
consider prescription drug ID laws or state oversight of pain management clinics.  
It should be noted that even though this model found a positive association between 
MMLs and opioid and/or alcohol related deaths, it is a very small association, especially when 
compared to the other covariates included in the model. The interaction term of percentage 
population that has finished no more than high school and percentage living in poverty was both 
positive and extremely large. In this context it is perhaps more appropriate to say that MMLs and 
attitudes towards marijuana in general have little effect on overdose deaths related to opioids or 
alcohol, especially compared to education and poverty levels. As discussed earlier MMLs are 
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considered an indicator of more lax attitudes towards marijuana use and this corresponds with a 
higher rate of use amongst high school students.2,1 Drug and alcohol abuse at young ages 
corresponds with higher rates of abuse and dependence later in life.21,5 Taking this into 
consideration, we might explain the positive association between MMLs and overdose deaths as 
the naturally occurring consequence of a population that is at a higher risk for drug abuse in 
general.  
This explanation seems to be more reasonable when we look at the secondary analysis of 
MMLs. Years since implementation has a negative effect on overdose rates meaning that 
multiple consecutive years of legal medical marijuana correspond with lower overdose rates. 
This corroborates the conclusions found in Bachhuber, et al.’s work.3 Though their work sought 
to provide a coefficient for each year post-MML passage, our study sought to provide a single 
coefficient based on the number of years a state had MMLs in place.  
It’s important to look at these results in the context of other studies as well. The study 
State Medical Marijuana Laws and the Prevalence of Opioids Detected Among Fatally Injured 
Drivers 28 looked at automobile fatalities from 1999-2013 in states with and without MMLs. 
Researchers found that in states with operational MMLs that opioid positivity, or drivers that 
tested positive for some opioid in fatal crashes, was significantly reduced in 21 to 40 years-olds. 
Furthermore, in the study Medical Marijuana Laws, Traffic Fatalities, and Alcohol Consumption 
7 found a nearly 12 percent decrease in any-BAC fatal crashes-per-100,000 licensed drivers and a 
14 percent decrease in high-BAC fatal crashes-per-100,000 licensed drivers in states with 
MMLs. This study also found that the legalization of medical marijuana is associated with a 
decrease in alcohol consumption especially among 20 – 29 year olds.7  
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Based on the results of this study it is reasonable to draw a number of conclusions. First, 
there is a clear positive relationship between MMLs and a higher rate of opioid, heroin and 
alcohol overdose rates but this relationship is small and likely due to the attitudes and behaviors 
that are necessarily present in order to get medical marijuana legalized. Every subsequent year 
after the passage of MMLs is associated with a stronger negative effect on these kinds of 
overdoses. We interpret this to mean that over time, as patients get registered, identification 
cards get dispersed, dispensaries open and the practice of prescribing and using medical 
marijuana becomes more commonplace, that the beneficial effects of medical marijuana with 
regards to overdose deaths become more pronounced. When considering these conclusions in the 
context of similar research, the idea that marijuana acts as a substitute for opioids, heroin and 
alcohol seems reasonable.  
Besides just focusing on the effect of MMLs on overdose deaths, understanding the 
effects of the demographic variables included in the models is also important. The inclusion of 
an interaction term, between the percentage of a state’s population living in poverty and the 
percentage of a state’s population with no more than a high school diploma, has a large positive 
effect on overdose deaths in all eight models specified. The size of this effect is quite large in all 
cases and dwarfs the individual negative coefficients present on poverty and education by 
themselves. This suggests that the overdose problem cannot be said to relate solely to poverty or 
education level. It would be incorrect to say that poverty by itself is an adequate predictor of 
these kinds of overdoses. Instead, our models seem to reinforce what has been posited by other 
studies, that the most at-risk groups for this kind of drug abuse are lower income whites with 
relatively little education.18  
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There are a few limitations to this analysis to consider when evaluating the results of this 
study. First, individuals’ ability to cross state lines is unaccounted for in this analysis. State-wide 
policies, specifically the presence of PDMPs, could affect the behaviors of drug-users and 
suppliers that live in relatively close proximity to state borders. Furthermore, this study did not 
account for differences in states’ MML policies. No distinction was made between states with 
MMLs during the study period, despite the fact that MMLs were not uniform in states where 
they were present. Lastly, since this analysis was done at the state level it is hard to make any 
conclusions based on urban vs. suburban and/or rural areas. States are not homogenous within 
themselves and it would be interesting to look at differences between urban and rural 
populations.  
In the future a number of next steps could be considered to further this analysis. It would 
be very useful to look at death-rates at the county-level rather than just the state-level, in order to 
account for differences in urban and rural populations. Analysis at this level can be difficult as 
more data is suppressed in lower-population subgroups however. This concept could be extended 
to look at quarter-year time intervals rather than full years as well. It would also be interesting to 
look at differences in MMLs. As stated earlier no distinction was made for differences in state-
wide MMLs and a more granular analysis of these policies could be very illuminating.  
In addressing the growing problem of overdoses related to opioids, heroin and/or alcohol, 
it is important to take into account the issues and conditions that have most influenced this 
problem. The conclusion of this study, and others that show that MMLs have a beneficial effect 
on overdoses, abuse rates and traffic fatalities related to opioid, heroin and alcohol abuse, should 
not be that medical marijuana is a cure-all for these issues. Instead, a more appropriate 
conclusion would be that while there is evidence that the presence of medical marijuana is 
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beneficial in reducing overdose deaths and drug abuse, material conditions such as poverty and 
education level are still much more important in predicting these problems. A public health 
approach to the issue of overdoses related to opioids, heroin or alcohol should be two pronged. 
First, efforts should be made to make drug policy more lenient. Marijuana has been shown to be 
a substitute, if an imperfect one, for both opioids and alcohol, and has reduced problems 
associated with these two substances. More leniency towards opioid and heroin abuse also has 
the added benefit of possibly saving the lives of more drug abusers. Second, it is clear that the 
most positive change would come from improving education and reducing poverty in areas hit 
hardest by this drug epidemic. This may fall outside the purview of public health, but it is clear 
that poverty and education are the two areas where improvement would see opioid, heroin and 
alcohol related deaths fall.  
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APPENDIX: TABLES AND REGRESSION DIAGNOSTICS 
Table 7. Overdose deaths with cause of death codes for opioids, heroin or alcohol by state 
Age-Adjusted Death rate/100000 
  
Year 
  
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
St
at
e 
AL 3.29 4.47 4.71 6.8 9.33 11.4 11.8 9.86 10.8 10.2 11.2 13.8 
AK 10.2 10.2 8.94 9.56 10.9 19.7 17.2 13.4 14.8 14.5 15 16.4 
AZ 9.02 9.41 9.83 10.5 11.2 11 12.9 14.5 13.9 14.3 15.7 14.9 
AR 4.2 5.65 6.49 7.64 8.49 10.4 10.7 9.8 9.9 10.1 8.16 10 
CA 5.91 5.9 5.97 6.2 7.71 7.87 8.4 8.19 8.28 7.46 8.32 8.24 
CO 6.86 6.24 8.17 8.64 10.9 11.2 11.8 10.2 13 12 11.9 12.3 
CT 6.34 7.11 6.02 7.87 9.2 8.7 8.31 7.6 8.04 9.12 13.6 15.7 
DE 6.76 4.86 5.53 7.61 9.16 12.5 11.9 13.3 13.8 12.1 16.3 17.1 
DC 5.15 7.5 3.85 6.57 4.67 6.23 . 9.7 9.88 9.17 10.7 12.3 
FL 9.06 9.38 9.7 10.4 11.8 12.9 13.6 13.6 12.6 10.3 9.84 10.5 
GA 4.97 5.2 5.62 6.74 7.61 7.81 8.39 8.74 8.81 8.42 8.48 9.29 
HI 3.52 4.71 5.59 3.97 6.62 5.81 5.91 6.14 7.84 5.73 6.05 5.52 
ID 5.21 5.15 5.17 7.02 7.08 7.6 8.6 9.15 9.19 9.96 10.2 9.56 
IL 3.31 4.19 4.59 7.5 6.3 7.35 8.23 7.54 7.49 8.13 9.74 11 
IN 5.03 6.34 7.51 8.71 10.3 11.4 12.4 11.6 13.1 13.6 14.5 16.3 
IA 1.81 2.12 2.97 4.18 4.32 5.55 5.53 6.58 6.35 7.16 7.43 7.63 
KS 3.83 5.78 6.16 6.5 7.4 6.98 9.52 7.66 8.29 9.23 9.98 10 
KY 11.5 10.7 13 14.6 15.2 16.3 16.5 21.9 23.6 23.1 21.6 23.2 
LA 9.5 9.8 12.1 13.6 16 12.9 11.4 11.7 11 10.6 15.4 14.3 
ME 7.76 8.94 9.64 9.84 10.2 11.6 10.7 8.18 8.86 9.22 11 15.5 
MD 3.25 4.63 5.46 7.38 9.29 8.75 9.37 9.17 9.66 11.2 12.3 15.6 
MA 3.38 3.45 4.31 6.75 8.16 7.42 7.66 7.35 8.27 9.04 10.4 15.7 
MI 5.22 6.23 7.16 8.98 9.77 10.4 12.3 11.5 12.6 11.9 13.8 16 
MN 2.75 2.89 3.26 3.89 4.98 6 6.66 6.09 7.57 7.04 7.91 7.52 
MS 5.98 6.47 7.06 9.94 9.62 9.84 9.67 9.64 9.34 9.82 9.66 10.4 
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 Table 7 Continued 
MO 6.74 6.94 7.66 9.32 9.53 11.1 11.8 14.1 12.9 12.9 14.1 15.2 
MT 8.32 8.37 7.24 7.29 9.49 12.5 12.4 9.31 12 9.54 10.2 9.21 
NE 2.11 1.96 3.5 3.86 4.21 4.88 5.34 5.65 6.51 6.11 5.33 5.34 
NV 8.79 10 11 11.1 13.6 14.4 15.7 16.3 18.2 16.9 15.6 14.5 
NH 5.54 5.26 6.78 7.1 9.41 6.58 10.1 9.04 11.2 11.4 12.1 23.3 
NJ 6.04 4.85 6.68 7.4 6.72 7.09 2.47 8.74 10.3 12.1 13.1 12.8 
NM 16.9 14.5 16.6 18.4 20.6 24.6 21.4 21.5 25.3 23.6 21.5 26.2 
NY 2.37 2.02 2.44 5.17 5.81 6.38 6.22 6.21 7.83 8.58 9.26 9.54 
NC 6.39 6.75 7.68 7.95 8.56 9.89 10.3 8.99 10.8 10.2 10.1 11.2 
ND . . . . 3.76 5.93 4.89 3.51 . . . 6.22 
OH 5.22 7.66 8.29 10.5 11.9 13.2 9.46 14.3 15.4 16.8 18.5 22.8 
OK 8.61 10.9 10.5 13.1 16.3 14.2 19.1 17.4 17 17.6 18 17.4 
OR 6.52 6.18 6.55 8.69 9.98 10.2 10.1 9.92 10.7 9.55 9.06 9.72 
PA 9.67 10.6 11.3 11.5 12.4 13 13.2 13.3 16.3 16.8 17.3 19.8 
RI 6.25 4.91 6.62 9.87 9.03 11.7 10.1 11.9 14.9 15.6 18.4 21.2 
SC 4.99 6.51 7.76 9.3 9.33 9.96 11.3 12.1 11 10.1 11 12.5 
SD . 3.55 2.83 4 2.84 5.63 5.24 5.18 5.54 4.84 6.14 5.6 
TN 8.05 9.13 10.3 11.4 12 11.9 12.1 13.6 14 14.4 15.1 16.4 
TX 4.98 5.08 5.51 6.37 6.57 6.27 7.5 7.28 7.65 6.65 6.69 7.02 
UT 12.7 11.9 15.7 15.1 17.3 16 16 14.2 16.8 18.3 18 18.2 
VT 7.79 5.94 5.38 9.16 7.14 9.49 7.67 6.47 9.56 8.21 12.6 12.1 
VA 5.07 5.11 5.09 5.37 6.34 6.85 6.6 5.42 7.38 6.8 8.06 9.03 
WA 8.13 9.46 9.46 10.4 11.3 11.8 11.9 10.2 11.3 10.9 11.2 10.6 
WV 12.6 15.1 8.59 17.4 20.1 23.2 11.1 26.8 33.2 29.4 29.7 32.8 
WI 4.4 4.89 5.9 7.18 8.63 8.22 8.36 8.74 9.71 10.5 12.8 12.7 
WY . 5.34 . 5.42 8.64 13.1 10.3 12.9 12.6 11.5 14.3 15.5 
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Figure 9. Residual diagnostics for opioid, heroin and alcohol primary overdose model, full population 
 
 
 
Figure 10. Residual diagnostics for opioid, heroin and alcohol primary overdose model, white population 
 33 
 
 
 
Figure 11. Residual diagnostics for opioid, heroin and alcohol secondary overdose model, full population 
 
 
Figure 12. Residual diagnostics for opioid, heroin and alcohol secondary overdose model, white population 
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Figure 13. Residual diagnostics for opioid and heroin primary overdose model, full population 
 
 
 
Figure 14. Residual diagnostics for opioid and heroin primary overdose model, white population 
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Figure 15. Residual diagnostics for opioid and heroin secondary overdose model, full population 
 
 
 
Figure 16. Residual diagnostics for opioid and heroin secondary overdose model, white population 
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